Author/Editor		Ul, Katja; Volčanšek, Gabriele; Gorenšek, Samo
Title		Vpliv zelo učinkovitega protiretrovirusnega zdravljenja, hunanega virusa imunske pomanjkljivosti (HIV) in drugih znanih dejavnikov tveganja na pojavnost osteopenije in osteoporoze pri slovenskih bolnikihm okuženih s HIV
Type		monografija
Place		Ljubljana
Publisher		Medicinska fakulteta
Publication year		2006
Volume		str. 53
Language		slo
Abstract		Background. Since the advent of potent antiretroviral therapy in combination regimens, many studies have shown that osteopenia and osteoporosis (low bone mineral density- BMD) are common in HIV infected patients. The etiology is multifactorial, osteopenia and osteoporosis have been attributed to the use of different antiretroviral regimens (especially those with protease inhibitors, PI), to HIV disease itself and to special patient characteristics. AIM. To estimate the prevalence of low BMD in Slovenian HIV infected male population, the effects of antiretroviral therapy, the HIV and other osteoporosis risk factors. Hypotesis. The prevalence of osteopenia and osteporosis in HIV infected patients is higher compared to the general population. Antiretroviral therapy, especially PI, is associated with higher risk of low BMD. The risk Factors for osteoporosis, such as alcohol abuse, smoking, lack of exercise, low calcium intake, hypogonadism and vitamin D deficiency, are frequent in HIV infected patients and contribute to bone loss. Methods. A cross-sectional study was performed in HIV-infected male population with 96 patients enrolled: 24 were HAART (highly active antiretroviral therapy) naive (group one), 37 were receiving HAART without PI (group two), 35 were receiving HAART that included a PI (group three), both for more than 12 months. All have been infected with HN for at least one year. Risk factors for osteoporosis using the interview questionnaire, medical documentation and anthropometrical measurements were evaluated. Bone mineral density of lumbar spine and hip was measured using dual-energy X-ray absorptiometry (DXA). Biochemical markers (intact parathyroid hormone, thyroid-stimulating hormone, C-terminal telopeptides of type-I collagen, skeletal alkaline phosphatase, osteocalcin, testosterone, vitamin D3, calcium, CD4 count and HIV viral load) were also assayed. (Abstract truncated at 2000 characters)
Descriptors		HIV INFECTIONS ANTIVIRAL AGENTS BONE DISEASES, METABOLIC OSTEOPOROSIS BONE DENSITY PARATHYROID HORMONES THYROTROPIN ALKALINE PHOSPHATASE OSTEOCALCIN TESTOSTERONE